Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 20, 2009Antimicrobial Agents and ChemotherapyOpen Access

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

View Full Paper
Ask AI
Bookmark
Share

Authors

NLNigel J. LivertonWeatherford CollegeSCSteven S. CarrollNational Maternity HospitalJDJillian DiMuzioImmunome (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Liverton et al. (2009) studied this question.

synapsesocial.com/papers/6a7267b4ac440176ef2aa826https://doi.org/10.1128/aac.00677-09
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)2008 · 175 citations
  2. 2Synergy of a Hepatitis C Virus (HCV) NS4A Antagonist in Combination with HCV Protease and Polymerase Inhibitors2008 · 38 citations
  3. 3Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)2008 · 49 citations